ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 763

Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis

Timothy Beukelman1, Fenglong Xie2, John Baddley3, Lang Chen4, Elizabeth S. Delzell5, Carlos Grijalva6, Melissa L. Mannion1, Nivedita M. Patkar7, Kenneth G. Saag8, Kevin L. Winthrop9 and Jeffrey R. Curtis2, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6Preventive Medicine, Vanderbilt University, Nashville, TN, 7Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL, 9Dept of Infectious Disease, Oregon Health & Science University, Portland, OR

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Juvenile idiopathic arthritis (JIA) and opportunistic infections

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: There may be an increased risk of opportunistic infections among children with juvenile idiopathic arthritis (JIA), especially with exposure to immunosuppressant medications. No controlled studies to address this question have been published. We determined incidence rates of selected opportunistic infections among children with and without JIA and examined the effects of immunosuppressant medications.

Methods: Using U.S. national Medicaid claims data from 2000 through 2005 we identified a cohort of children with JIA based on physician diagnosis codes and dispensed medications. We defined a non-JIA comparator cohort of children diagnosed with attention deficit hyperactivity disorder. All subjects had a 3 month baseline period prior to study follow-up to assess for prevalent opportunistic infections (which excluded patients from analysis) and current medication exposures. All medication exposures to methotrexate (MTX), TNF inhibitors, and systemic glucocorticoids (GC) were considered current for 30 days past the days supplied by the last filled prescription. Hospitalized and outpatient incident opportunistic infections were identified using physician diagnosis or hospital discharge codes. Identification of some infections (mycoses, tuberculosis, and herpes zoster) also required evidence of treatment with specific antimicrobials within 90 days. We calculated infection incidence rates (IR). The rates in the non-JIA comparator cohort were standardized to the age, sex, and race distribution of the JIA cohort. We calculated incidence rate ratios (IRR) to compare infection rates.

Results: The JIA cohort included 8,503 children with 14,370 person-years of follow-up; 1,392 used TNF inhibitors and 3,491 used MTX during follow-up. The non-JIA comparator cohort included 360,362 children with 490,939 person-years of follow-up. When all opportunistic infections were considered together as a single outcome, there were 42 infections in the JIA cohort (IR 300 [216-406] per 100,000; IRR 2.4 [1.7-3.3] versus non-JIA comparator). Among all children with JIA, there were no identified infections with Aspergillus, Blastomyces, Histoplasma, Cryptococcus, Legionella, Listeria, JC virus, or tuberculosis. We identified 1 infection each (IR 7 per 100,000) with Nocardia, non-tuberculous mycobacteria, Toxoplasma, and Pneumocystis. We identified 3 infections with Coccidioides (IR 21 per 100,000; IRR 101 [8.1-5319] versus non-JIA comparator); 5 infections with Salmonella(IR 35 per 100,000; IRR 3.8 [1.2-9.5]); and 32 cases of herpes zoster (IR 225 per 100,000; IRR 2.1 [1.4-3.0]). Among children with JIA, herpes zoster was not strongly associated with current use of GC (IRR 1.8 [0.6-4.5] versus no current GC use), MTX (IRR 1.4 [0.5-3.6] versus no current MTX or TNF inhibitor use), or TNF inhibitors (IRR 2.2 [0.7-6.9] versus current MTX use without current TNF inhibitor use).

Conclusion: Opportunistic infections are rare among children with JIA. Nevertheless, children with JIA had a higher rate of opportunistic infections, including Coccidioides, Salmonella, and herpes zoster, than children without JIA. Herpes zoster was not strongly associated with specific immunosuppressant medications used to treat JIA.


Disclosure:

T. Beukelman,

Pfizer Inc,

2,

Novartis Pharmaceutical Corporation,

5,

Genentech and Biogen IDEC Inc.,

5;

F. Xie,
None;

J. Baddley,

Abbott Immunology Pharmaceuticals,

5,

Merck Pharmaceuticals,

5;

L. Chen,
None;

E. S. Delzell,

Amgen,

2;

C. Grijalva,
None;

M. L. Mannion,
None;

N. M. Patkar,
None;

K. G. Saag,

Amgen,

5,

AstraZeneca,

5,

Eli Lilly and Company,

5,

Genentech and Biogen IDEC Inc.,

5,

Sanofi-Aventis Pharmaceutical,

5,

Merck Pharmaceuticals,

5,

Novartis Pharmaceutical Corporation,

5,

Savient Pharmaceuticals,

5,

Ardea Biosciences,

5,

Regeneron,

5;

K. L. Winthrop,

Pfizer Inc,

2,

Amgen,

5,

Pfizer Inc,

5,

Abbott Immunology Pharmaceuticals,

5,

Wyeth Pharmaceuticals,

5;

J. R. Curtis,

Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,

5,

Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-selected-opportunistic-infections-among-children-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology